NMDA receptor modulator (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "NMDA receptor modulator" in English language version.

refsWebsite

Global rank English rank

2^nd place

4^th place

1^st place

11^th place

8^th place

low place

3,257^th place

3,398^th place

4,032^nd place

6,573^rd place

low place

low place

ama-assn.org

Heresco-Levy, Uriel; Javitt, Daniel C.; Ermilov, Marina; Mordel, Clara; Silipo, Gail; Lichtenstein, Michael (1999). "Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia". Archives of General Psychiatry. 56 (1): 29–36. doi:10.1001/archpsyc.56.1.29. PMID 9892253.

"Amino Acid Glycine". Archived from the original on 2011-08-11. Retrieved 2010-05-31.

Heresco-Levy, Uriel; Javitt, Daniel C.; Ermilov, Marina; Mordel, Clara; Silipo, Gail; Lichtenstein, Michael (1999). "Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia". Archives of General Psychiatry. 56 (1): 29–36. doi:10.1001/archpsyc.56.1.29. PMID 9892253.
Evins, A. E.; Fitzgerald, S. M.; Wine, L.; Rosselli, R.; Goff, D. C. (2000). "Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia". American Journal of Psychiatry. 157 (5): 826–828. doi:10.1176/appi.ajp.157.5.826. PMID 10784481. S2CID 26013829. Archived from the original on 2012-09-26. Retrieved 2010-05-31.
Patil, Sandeep T; Lu Zhang; Ferenc Martenyi; Stephen L. Lowe; Kimberley A. Jackson; Boris V. Andreev; Alla S. Avedisova; Leonid M. Bardenstein; Issak Y. Gurovich; Margarita A. Morozova; Sergey N. Mosolov; Nikolai G. Neznanov; Alexander M. Reznik; Anatoly B. Smulevich; Vladimir A. Tochilov; Bryan G. Johnson; James A. Monn; Darryle D. Schoepp (September 2007). "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" (PDF). Nature Medicine. 13 (9). Nature Publishing Group: 1102–1107. doi:10.1038/nm1632. PMID 17767166. S2CID 6417333. Archived from the original (PDF) on 2017-01-16. Retrieved 2009-02-01.

Heresco-Levy, Uriel; Javitt, Daniel C.; Ermilov, Marina; Mordel, Clara; Silipo, Gail; Lichtenstein, Michael (1999). "Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia". Archives of General Psychiatry. 56 (1): 29–36. doi:10.1001/archpsyc.56.1.29. PMID 9892253.
Evins, A. E.; Fitzgerald, S. M.; Wine, L.; Rosselli, R.; Goff, D. C. (2000). "Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia". American Journal of Psychiatry. 157 (5): 826–828. doi:10.1176/appi.ajp.157.5.826. PMID 10784481. S2CID 26013829. Archived from the original on 2012-09-26. Retrieved 2010-05-31.
Patil, Sandeep T; Lu Zhang; Ferenc Martenyi; Stephen L. Lowe; Kimberley A. Jackson; Boris V. Andreev; Alla S. Avedisova; Leonid M. Bardenstein; Issak Y. Gurovich; Margarita A. Morozova; Sergey N. Mosolov; Nikolai G. Neznanov; Alexander M. Reznik; Anatoly B. Smulevich; Vladimir A. Tochilov; Bryan G. Johnson; James A. Monn; Darryle D. Schoepp (September 2007). "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" (PDF). Nature Medicine. 13 (9). Nature Publishing Group: 1102–1107. doi:10.1038/nm1632. PMID 17767166. S2CID 6417333. Archived from the original (PDF) on 2017-01-16. Retrieved 2009-02-01.

Patil, Sandeep T; Lu Zhang; Ferenc Martenyi; Stephen L. Lowe; Kimberley A. Jackson; Boris V. Andreev; Alla S. Avedisova; Leonid M. Bardenstein; Issak Y. Gurovich; Margarita A. Morozova; Sergey N. Mosolov; Nikolai G. Neznanov; Alexander M. Reznik; Anatoly B. Smulevich; Vladimir A. Tochilov; Bryan G. Johnson; James A. Monn; Darryle D. Schoepp (September 2007). "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" (PDF). Nature Medicine. 13 (9). Nature Publishing Group: 1102–1107. doi:10.1038/nm1632. PMID 17767166. S2CID 6417333. Archived from the original (PDF) on 2017-01-16. Retrieved 2009-02-01.

Evins, A. E.; Fitzgerald, S. M.; Wine, L.; Rosselli, R.; Goff, D. C. (2000). "Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia". American Journal of Psychiatry. 157 (5): 826–828. doi:10.1176/appi.ajp.157.5.826. PMID 10784481. S2CID 26013829. Archived from the original on 2012-09-26. Retrieved 2010-05-31.

Evins, A. E.; Fitzgerald, S. M.; Wine, L.; Rosselli, R.; Goff, D. C. (2000). "Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia". American Journal of Psychiatry. 157 (5): 826–828. doi:10.1176/appi.ajp.157.5.826. PMID 10784481. S2CID 26013829. Archived from the original on 2012-09-26. Retrieved 2010-05-31.
Patil, Sandeep T; Lu Zhang; Ferenc Martenyi; Stephen L. Lowe; Kimberley A. Jackson; Boris V. Andreev; Alla S. Avedisova; Leonid M. Bardenstein; Issak Y. Gurovich; Margarita A. Morozova; Sergey N. Mosolov; Nikolai G. Neznanov; Alexander M. Reznik; Anatoly B. Smulevich; Vladimir A. Tochilov; Bryan G. Johnson; James A. Monn; Darryle D. Schoepp (September 2007). "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" (PDF). Nature Medicine. 13 (9). Nature Publishing Group: 1102–1107. doi:10.1038/nm1632. PMID 17767166. S2CID 6417333. Archived from the original (PDF) on 2017-01-16. Retrieved 2009-02-01.

Evins, A. E.; Fitzgerald, S. M.; Wine, L.; Rosselli, R.; Goff, D. C. (2000). "Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia". American Journal of Psychiatry. 157 (5): 826–828. doi:10.1176/appi.ajp.157.5.826. PMID 10784481. S2CID 26013829. Archived from the original on 2012-09-26. Retrieved 2010-05-31.
"Amino Acid Glycine". Archived from the original on 2011-08-11. Retrieved 2010-05-31.
Patil, Sandeep T; Lu Zhang; Ferenc Martenyi; Stephen L. Lowe; Kimberley A. Jackson; Boris V. Andreev; Alla S. Avedisova; Leonid M. Bardenstein; Issak Y. Gurovich; Margarita A. Morozova; Sergey N. Mosolov; Nikolai G. Neznanov; Alexander M. Reznik; Anatoly B. Smulevich; Vladimir A. Tochilov; Bryan G. Johnson; James A. Monn; Darryle D. Schoepp (September 2007). "Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" (PDF). Nature Medicine. 13 (9). Nature Publishing Group: 1102–1107. doi:10.1038/nm1632. PMID 17767166. S2CID 6417333. Archived from the original (PDF) on 2017-01-16. Retrieved 2009-02-01.